Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

NCT00595465 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

NCT00604708 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

NCT00776230 ·Status: COMPLETED ·Phase: PHASE3

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

NCT00596271 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis

NCT06825312 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine

NCT03294135 ·Status: COMPLETED ·Phase: PHASE4

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

NCT01559831 ·Status: WITHDRAWN ·Phase: PHASE1

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

NCT01246479 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

NCT01047839 ·Status: COMPLETED ·Phase: PHASE3

Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children

NCT01954810 ·Status: UNKNOWN ·Phase: PHASE4

Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

NCT00311493 ·Status: COMPLETED ·Phase: PHASE4

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666 ·Status: COMPLETED ·Phase: PHASE2

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

NCT04817917 ·Status: UNKNOWN ·Phase: PHASE4

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

NCT04648241 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

NCT00621764 ·Status: COMPLETED ·Phase: PHASE2

Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults

NCT00387634 ·Status: COMPLETED ·Phase: PHASE4

Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country

NCT01296360 ·Status: COMPLETED ·Phase: PHASE3

A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)

NCT00835380 ·Status: COMPLETED ·Phase: PHASE3

Purified Inactivated Japanese Encephalitis Vaccine

NCT04223037 ·Status: UNKNOWN ·Phase: PHASE3

Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants

NCT00480324 ·Status: COMPLETED ·Phase: PHASE3

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

NCT02933710 ·Status: COMPLETED

Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children

NCT01408537 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

NCT02602652 ·Status: COMPLETED ·Phase: NA

6-year Antibody Check After Third Vaccination Against Japanese Encephalitis

NCT02039440 ·Status: COMPLETED ·Phase: PHASE4

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

NCT01900444 ·Status: COMPLETED ·Phase: PHASE3